Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060520 | 0.89 | HDAC1 (0.80) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL1064761 | 0.88 | HDAC1 (0.79) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL1064435 | 0.80 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL1065031 | 0.80 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL3551848 | 0.79 | HDAC1 (0.66) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL3538804 | 0.78 | HDAC1 (0.64) | HDAC1HDAC6HDAC2 | |
| SCHEMBL1065378 | 0.78 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL1064696 | 0.77 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC3HDAC4 | |
| SCHEMBL3546281 | 0.77 | HDAC1 (0.66) | HDAC1 | |
| SCHEMBL1065878 | 0.77 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| CN-1578663-B | Histone deacetylase inhibitors | METHYLGENE INC | 2011-05-25 | — | — | CN | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| CN-101851173-A | Inhibitors of histone deacetylase | METHYLGENE INC | 2010-10-06 | — | — | CN | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| CN-1578663-A | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2005-02-09 | — | — | CN | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1429765-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC6 6/4885HDAC2 5/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC6 6/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.